News | September 03, 2023
BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
The inspection has concluded successfully on 1st September 2023 without any critical/major observation
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
The approval bolsters the company's Mycophenolate Mofetil portfolio
Pirfenidone Capsules had estimated annual sales of USD 95 million in the US
Prasugrel tablets are indicated to reduce the rate of thrombotic CV events
Propranolol LA is a generic equivalent of Inderal LA
Topiramate is the generic version of Supernus Pharmaceuticals’ Trokendi XR
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Subscribe To Our Newsletter & Stay Updated
